Status:
COMPLETED
Muscle Protein Synthesis in Dialysis Patients
Lead Sponsor:
University of Illinois at Urbana-Champaign
Conditions:
Muscle Loss
Eligibility:
All Genders
20-80 years
Brief Summary
The most severe form of chronic renal failure is end-stage-renal-disease with maintenance hemodialysis (MHD) as the most common treatment strategy. MHD patients experience a number of metabolic and ph...
Detailed Description
On the day of the infusion trial, participants will report to the laboratory at 0700 h after an overnight fast. MHD patients will be studied \~24 h after their dialysis treatment. A Teflon catheter wi...
Eligibility Criteria
Inclusion
- Aged 20-80 years (both healthy controls and MHD patients)
- Medical clearance from a Nephrologist at their respective dialysis clinic to participate (MHD patients)
Exclusion
- Known allergies to egg consumption (both healthy controls and MHD patients)
- Phenylketonuria (both healthy controls and MHD patients)
- Vegans (both healthy controls and MHD patients)
- Diagnosed GI tract diseases (healthy controls)
- Recent (1 year) participation in amino acid tracer studies (both healthy controls and MHD patients)
- Predisposition to hypertrophic scarring or keloid formation (both healthy controls and MHD patients)
- Diabetes (healthy controls)
- Pregnancy (both healthy controls and MHD patients)
Key Trial Info
Start Date :
January 18 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2018
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT03478722
Start Date
January 18 2017
End Date
April 1 2018
Last Update
May 1 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Freer Hall
Urbana, Illinois, United States, 61801